Abstract
Prostate cancer (PCa) is the most common cancer in the male population in Western countries, second to skin cancer. Hormonal therapy allows long-lasting and effective control of cancer-related symptoms in advanced stages; however, in almost all patients with metastatic PCa the disease will progress when it becomes castration-resistant (CRPC). Chemotherapy with docetaxel was a turning point in CRPC, as, for the first time, it resulted in an increased survival time in comparison with mitoxantrone and prednisone. Combination therapy with docetaxel and prednisone is the first-line treatment of choice. Once the cancer has progressed, there is no clear alternative, although some new agents have shown promise in the treatment of this type of cancer. This review will provide an overview of the current status of CRPC, including clinical status, prognosis, firstline treatment and new second-line treatment options.
Similar content being viewed by others
References
Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
Cooperberg MR, Moul JW, Carroll PR (2005) The changing face of prostate cancer. J Clin Oncol 23:8146–8151
Uchio EM, Aslan M, Wells CK et al (2010) Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med 170:1390–1395
Eisenberger MA, Simon R, O’Dwyer PJ, Friedman HA (1985) A re-evaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827–841
Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098–1109
Tannock IF, de Wit R, Berry WR et al; on behalf of the TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512
Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520
Berry DL, Moinpour CM, Jiang CS et al (2006) Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 24:2828–2835
Rosenberg JE, Weinberg VK, Kelly WK et al (2007) Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110:556–563
Tannock IF, Osoba D, Stockler MR et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormoneresistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764
Scher HI, Halabi S, Tannock I et al (2008) Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148–1159
Van Allen EM, Ryan CJ (2009) Novel secondary hormonal therapy in advanced prostate cancer: an update. Curr Opin Urol 19:315–321
Hotte SJ, Saad F (2001) Current management of castrate-resistant prostate cancer. Curr Oncol 17[Suppl 2]:S72–79
Scher HI, Kelly WK (1993) Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566–1572
Small EJ, Halabi S, Dawson NA et al (2004) Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALBG 9583). J Clin Oncol 22:1025–1033
Sartor AO, Tangen CM, Hussain MH et al (2008) Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 112:2393–2400
Suzuki H, Okihara K, Miyake H et al (2008) Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 180:921–927
Hussain M, Wolf M, Marshall E et al (1994) Effects of continued androgen deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormonerefractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 12:1868–1875
Oh WK, Kanthoff PW, Weinberg V et al (2004) Prospective, multicentre, randomized phase II trial of the herbal supplement PC-SPES and diethylbestrol in patients with androgen-independent prostate cancer. Clin Oncol 22:3705–3712
Orlando M, Chacon A, Salum G, Chacon DR (2000) Low dose continuous oral fosfestrol is highly active in hormone refractory prostate cancer. Ann Oncol 11:177–181
Kantoff PW, Halabi S, Conaway M et al (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B9182 study. J Clin Oncol 17:2506–2513
Ryan CJ, Eisenberger M (2005) Chemotherapy for hormone-refractory prostate cancer: now it’s a question of when? J Clin Oncol 23:8242–8246
Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate level of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148
Scher HI, Warren M, Heller G (2007) The association between measures of progression and survival in castrate metastatic prostate cancer. Clin Cancer Res 13:1488–1492
Armstrong AJ, Garret-Mayer E, de Wit R et al (2010) Prediction of survival following first line chemotherapy in men with castration resistant metastatic prostate cancer. Clin Cancer Res 16: 203–211
Berthold DR, Pond GR, de Wit R et al (2008) Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 19:1749–1753
Fontana A, Galli L, Fioravanti A et al (2009) Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 15:4954–4962
Sternberg CN (2007) Satraplatin demonstrates a significant clinical benefit in patients with hormone-refractory prostate cancer. Proc Am Soc Clin Oncol
Attard G, Greystoke A, Kaye S, de Bono J (2006) Update on tubulin-binding agents. Pathol Biol (Paris) 54:72–84
Bissery M-C (2001) Preclinical evaluation of new taxoids. Curr Pharm Des 7:1251–1257
de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 376:1147–1154
FDA Center for Drug Evaluation and Research. Approval Package for: Jevtana. June 17, 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/201023s000Approv. pdf. Accessed February 2, 2011
de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005
Scher HI, Beer TM, Higano CS et al (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375:1437–1446
Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422
Chi KN, Hotte SJ, Yu EY et al (2010) Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28:4247–4254
Kantoff PW, Schuetz TJ, Blumenstein BA et al (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA targeted immunotherapy in metastatic castrationresistant prostate cancer. J Clin Oncol 28:1099–1105
Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822
Sonpavde G, Sternberg CN (2011) Contemporary management of metastatic castration-resistant prostate cancer. Curr Opin Urol 21:241–247
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by an unrestricted educational grant from MSD Oncology
Rights and permissions
About this article
Cite this article
Carles, J., Castellano, D., Climent, M.Á. et al. Castration-resistant metastatic prostate cancer: current status and treatment possibilities. Clin Transl Oncol 14, 169–176 (2012). https://doi.org/10.1007/s12094-012-0780-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-012-0780-8